King's College London documents hospital trials at under 10% industry cost for generic repurposing

The Cambridge Law Journal paper from King's College London maps a parallel innovation track where academic and NHS sites select already-approved molecules, secure grant and ethics approval, and complete pivotal trials without patent-driven capital requirements. Documented cases include bevacizumab for age-related macular degeneration, tamoxifen for breast cancer prevention, and colchicine derivatives for COVID-19 indications, each executed after generic entry reduced per-patient drug costs to under £5 daily.

Industry phase 3 oncology trials average £150-300 million; the studied academic cohorts completed equivalent late-stage work for £10-25 million, primarily through salaried clinician time, existing NHS infrastructure, and lower regulatory overhead. This cost differential arises because financial viability of the sponsor does not hinge on market exclusivity, removing the risk premium embedded in company-funded programs.

The model directly links academic output to hospital formularies without intermediary pricing layers, cutting patient and payer exposure by 85-95% once guidance is issued. Regulatory bodies have yet to standardize abbreviated pathways for these investigator-initiated files, leaving adoption dependent on local commissioning decisions rather than central label updates.

Operational scaling requires dedicated repurposing units inside NHS trusts linked to university ethics committees, with 12-18 month trial timelines already demonstrated in the UK cohort.